Home|Journals|Articles by Year|Audio Abstracts

Review Article

J App Pharm Sci. 2023; 13(8): 101-112

The in-silico potential of Andrographis paniculata phytocompounds as antiviral for the treatment of COVID-19: A systematic review

Shafa Shavira, Septi Handayani, Fatmaria Fatmaria.

Cited by 3 Articles

Since the outbreak of COVID-19, many studies have been conducted to develop definitive therapeutic agents for this viral disease. The in-silico method has become the best solution for the initial step in discovering potential antiviral compounds. Several phytocompounds from a medicinal plant, Andrographis paniculata, were reported to have activity inhibiting SARS-CoV-2 proteins. The present systematic review aims to determine the potency of A. paniculata compounds against COVID-19. We undertook a systematic search in two databases, Pubmed and Google Scholar, and included original articles that applied in silico methods for phytocompounds of A. paniculata in COVID-19. Twenty-nine original articles were included in the systematic review. We report that 50 of the 107 A. paniculata phytocompounds (46.73%) against SARS‐CoV-2. We found five proteins target of SARS-CoV-2 are highly conserved structures mostly used in the articles, which are main protease, papain-like protease, RNA-dependent RNA-polymerase, Nsp15, and spike protein. Six A. paniculata phytocompounds have an inhibition activity of that five protein targets including andrographolide, neoandrographolide, isoandrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-didehydroandrographolide, and andrographidin C as main diterpenoid compounds. Based on the literature evidence, some of the A. paniculata phytocompounds could be potential antiviral agents due to their strong binding affinities and stable conformations towards SARS-CoV-2 proteins.

Key words: Andrographis paniculata, in silico, antiviral, COVID-19, systematic review.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.